DVS Sciences announces business agreement with Cytobank

DVS Sciences, Inc., a privately held innovator and manufacturer of novel CyTOF® multi-parameter single-cell analyzers and reagents for biological research, today announced a business agreement with Cytobank, Inc., a privately held developer of cloud based scientific, informatics and software solutions for the flow cytometry market.    

The CyTOF mass cytometry platform developed by DVS Sciences enables revolutionary understanding of cellular dynamics of disease states, identification of stem cells and unprecedented insight into other biological systems using metal conjugated antibodies bound to cells and analyzed by time of flight mass spectrometry. The technology uniquely has the capability to simultaneously measure up to 100 cell biomarkers in single cells at up to 1000 cells per second. The software platform created by Cytobank enables researchers to analyze and manage the data acquired on CyTOF instruments using a novel cloud computing platform integrated with proprietary algorithms for data analysis. Together, DVS Sciences and Cytobank will co-develop and release an integrated solution, "DVS Cytobank™", that automatically analyzes and manages the large data sets resulting from CyTOF instruments, while concurrently providing information on reagent panels and protocols. The new venture enables and simplifies the analysis of the massively multi-parameter mass cytometry data. DVS Cytobank is a proprietary implementation developed specifically for mass cytometry data, capitalizing on the Cytobank platform and provided by DVS Sciences directly to researchers using the CyTOF platform.